Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study

被引：10

作者：

Fasching, P. A. ^{[1
]}

Fehm, T. ^{[2
,39
]}

Kellner, S. ^{[3
]}

de Waal, J. ^{[3
]}

Rezal, M. ^{[4
]}

Baler, B. ^{[3
]}

Baake, G. ^{[5
]}

Kolberg, H. -C ^{[6
]}

Guggenberger, M. ^{[7
]}

Warm, N. ^{[3
,8
,9
]}

Harbeck, N. ^{[29
]}

Wuerstlein, R. ^{[10
]}

Deuker, J. -U ^{[11
,21
]}

Dall, P. ^{[12
,31
]}

Richter, B. ^{[32
]}

Wachsmann, G. ^{[13
]}

Brucker, C. ^{[14
]}

Siebers, J. W. ^{[15
]}

Fersis, N. ^{[16
]}

Kuhn, T. ^{[17
]}

Wolf, C. ^{[18
]}

Vollert, H. -W ^{[19
]}

Breitbach, G. -P ^{[20
,22
]}

Janni, W. ^{[21
]}

Landthaler, R. ^{[22
]}

Kohls, A. ^{[23
,33
]}

Rezek, D. ^{[24
,28
]}

Nosslet, T. ^{[25
,27
]}

Fischer, G. ^{[26
]}

Henschen, S. ^{[28
]}

Praetz, T. ^{[29
]}

Heyl, V. ^{[35
]}

Kuehn, T. ^{[30
,32
]}

Krauss, T. ^{[31
]}

Thomssen, C. ^{[32
]}

Kuemmel, S. ^{[33
]}

Hohn, A. ^{[34
]}

Tesch, H. ^{[35
]}

Mundhenke, C. ^{[31
]}

Hein, A. ^{[1
,33
]}

Rauh, C. ^{[1
]}

Bayer, C. M. ^{[1
]}

Jacob, A. ^{[37
]}

Schmidt, K. ^{[37
]}

Belleville, E. ^{[31
]}

Hadji, P. ^{[38
]}

Wallwiener, D. ^{[39
]}

Grischice, E. -M ^{[36
,39
]}

Beckmann, M. W. ^{[1
]}

Brucker, S. Y.

机构：

[1] Univ Erlangen Nurnberg, Univ Brustzentrum Franken, Frauenklin, Comprehens Canc Ctr Erlangen EMN,Univ Klinikum Er, D-91054 Erlangen, Germany

[2] Univ Frauenklin Dusseldorf, Dusseldorf, Germany

[3] Frauenklin Klinikum Dachau, Dachau, Germany

[4] Luisenkrankenhaus Dusseldorf, Dusseldorf, Germany

[5] Klinikum Pinneberg, Pinneberg, Germany

[6] Marienhosp Bottrop, Bottrop, Germany

[7] Klinikum Tuttlingen, Tuttlingen, Germany

[8] Univ Frauenklin Koln, Brustzentrum, Cologne, Germany

[9] Klinken Stadt Koln gGmbH Holweide, Brustzentrum, Cologne, Germany

[10] Univ Munich, Brustzentrum, Frauenkliniken Grosshadern & Maistr Innenstad, Munich, Germany

[11] Klinikum Luneburg, Frauenklin, Luneburg, Germany

[12] Elblandkliniken Meissen Radebeul Standort Radebeu, Radebeul, Germany

[13] Kreiskrankenhaus Boblingen, Boblingen, Germany

[14] Paracelsus Med Privatuniv, Univ Klin Frauenheilkunde, Nurnberg, Germany

[15] St Josefklin Offenburg, Frauenklin, Offenburg, Germany

[16] Klinikum Bayreuth GmbH, Comprehens Canc Ctr Erlangen EMN, Frauenklin, Bayreuth, Germany

[17] Karl Olga Krankenhaus, Stuttgart, Germany

[18] Med Zentrurn Ulm, Ulm, Germany

[19] Klinikum Friedrichshafen, Friedrichshafen, Germany

[20] Stadt Klinikum Neunkirchen Gynakol & Geburtshilfe, Neunkirchen, Germany

[21] Univ Ulm Klinikum, Frauenklin, Ulm, Germany

[22] Gynakol Praxis Kreisklin, Krumbach, Germany

[23] Evangel Krankenhaus Ludwigsfelde Teltow, Ludwigsfelde, Germany

[24] Marien Hosp Wesel, Wesel, Germany

[25] Frauenklin Kreiskrankenhaus Hameln, Hameln, Germany

[26] Landkreis Mittweida Krankenhaus gGmbH, Mittweida, Germany

[27] Johanniter Krankenhaus Genthin Stendal gGmbH, Stendal, Germany

[28] Praxis Dr Praetz, Bad Mergenlheim, Germany

[29] Asklepios Paulinen Klin Wiesbaden, Wiesbaden, Germany

[30] Stadt Kliniken Esslingen aN, Frauenklin, Esslingen, Germany

[31] Frauenklin Lippe, Lippe, Germany

[32] Univ Klin Halle Wittenberg, Frauenklin, Halle, Germany

[33] Evang Huyssens Stiftung Knappschaft GmbH, Kliniken Essen Mitte, Brustzentrum, Essen, Germany

[34] Kreiskrankenhaus Rendsburg, Rendsburg, Germany

[35] Onkol Bethanien, Frankfurt, Germany

[36] Univ Klinikum Schleswig Holstein Campus Kiel, Kiel, Germany

[37] Novartis Pharma GmbH, Nurnberg, Germany

[38] Krankenhaus NW Frankfurt, Klin Gynakol & Gebursthilfe, Frankfurt, Germany

[39] Univ Frauenklin Tubingen, Tubingen, Germany

来源：

GEBURTSHILFE UND FRAUENHEILKUNDE | 2014年 / 74卷 / 12期

关键词：

breast cancer; aromatase inhibitor; compliance; endocrine therapy; ADJUVANT ENDOCRINE THERAPY; PATIENTS ANASTROZOLE COMPLIANCE; RANDOMIZED-TRIAL; TAMOXIFEN THERAPY; PACT PROGRAM; WOMEN; EXEMESTANE; COMBINATION; ADHERENCE;

D O I：

10.1055/s-0034-1383401

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Introduction: The EvaluateTM study (Evaluation of therapy management and patient compliance in postmenopausal hormone receptor-positive breast cancer patients receiving letrozole treatment) is a prospective, non-interventional study for the assessment of therapy management and compliance in the routine care of postmenopausal women with invasive hormone receptor-positive breast cancer receiving letrozole. The parameters for inclusion in the study are presented and discussed here. Material and Methods: Between January 2008 and December 2009 a total of 5045 patients in 310 study centers were recruited to the EvaluateTM study. Inclusion criteria were hormone receptor-positive breast cancer and adjuvant treatment or metastasis. 373 patients were excluded from the analysis for various reasons. Results: A total of 4420 patients receiving adjuvant treatment and 252 patients with metastasis receiving palliative treatment were included in the study. For 4181 patients receiving adjuvant treatment, treatment with the aromatase inhibitor letrozole commenced immediately after surgery (upfront). Two hundred patients had initially received tamoxifen and started aromatase inhibitor treatment with letrozole at 1-5 years after diagnosis (switch), und 39 patients only commenced letrozole treatment 5-10 years after diagnosis (extended endocrine therapy). Patient and tumor characteristics were within expected ranges, as were comorbidities and concurrent medication. Conclusion: The data from the EvaluateTM study will offer a good overview of therapy management in the routine care of postmenopausal women with hormone receptor-positive breast cancer. Planned analyses will look at therapy compliance and patient satisfaction with how information is conveyed and the contents of the conveyed information.

引用

页码：1137 / 1143

页数：7

共 50 条

[41] Adjuvant Endocrine Therapy of Perimenopausal and Recently Postmenopausal Women With Hormone Receptor-Positive Breast Cancer
Pan, Kathy
Chlebowski, Rowan T.
CLINICAL BREAST CANCER, 2014, 14 (03) : 147 - 153
[42] Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer
Gil J.M.
Rubio-Terrés C.
del Castillo-Saiz A.
González P.
Canorea F.
Clinical and Translational Oncology, 2006, 8 (5) : 339 - 348
[43] Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer
Wunderle, Marius
Pretscher, Jutta
Brucker, Sara Y.
Volz, Bernhard
Hartmann, Arndt
Fiessler, Cornelia
Hein, Alexander
Haeberle, Lothar
Jud, Sebastian M.
Lux, Michael P.
Janni, Wolfgang
Loehberg, Christian R.
Hartkopf, Andreas D.
Walter, Christina B.
Baake, Gerold
Fridman, Alexander
Malter, Wolfram
Wuerstlein, Rachel
Harbeck, Nadia
Hoffmann, Oliver
Kuemmel, Sherko
Martin, Bernhard
Thomssen, Christoph
Graf, Heiko
Wolf, Christopher
Bayer, Christian M.
Hack, Carolin C.
Almstedt, Katrin
Gass, Paul
Heindl, Felix
Brodkorb, Tobias F.
Nabieva, Naiba
Lindner, Christoph
Kolberg, Hans-Christian
Krabisch, Petra
Weigel, Michael
Steinfeld-Birg, Dieter
Kohls, Andreas
Brucker, Cosima
Schulz, Volker
Fischer, Gunnar
Pelzer, Volker
Wallwiener, Diethelm
Rack, Brigitte
Fehm, Tanja
Rody, Achim
Maass, Nicolai
Beckmann, Matthias W.
Fasching, Peter A.
Rauh, Claudia
BREAST CANCER RESEARCH AND TREATMENT, 2019, 174 (02) : 453 - 461
[44] Everolimus in the treatment of hormone receptor-positive breast cancer
Chavez-MacGregor, Mariana
Gonzalez-Angulo, Ana Maria
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (12) : 1835 - 1843
[45] Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review
S. J. Ioannides
P. L. Barlow
J. M. Elwood
D. Porter
Breast Cancer Research and Treatment, 2014, 147 : 237 - 248
[46] Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer
Kaklamani, Virginia G.
Gradishar, William J.
ONCOLOGIST, 2017, 22 (05) : 507 - 517
[47] Management of hormone receptor-positive, HER2-negative early breast cancer
Walsh, Elaine M.
Smith, Karen L.
Stearns, Vered
SEMINARS IN ONCOLOGY, 2020, 47 (04) : 187 - 200
[48] Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Stearns, Vered
Brufsky, Adam M.
Verma, Shailendra
Cotter, Matthew J.
Lu, Dongrui R.
Dequen, Florence
Joy, Anil Abraham
CLINICAL BREAST CANCER, 2018, 18 (06) : E1239 - E1245
[49] Genetics, Treatment, and New Technologies of Hormone Receptor-Positive Breast Cancer
Sebastian, William
Forchette, Lauren
Donoughe, Kelsey
Lun, Yibei
Verma, Anisha
Liu, Tuoen
CANCERS, 2023, 15 (04)
[50] Endocrine therapy and radiotherapy use among older women with hormone receptor-positive, clinically node-negative breast cancer
Wei, Mei
Wang, Xuechen
Zimmerman, Danielle N.
Burt, Lindsay M.
Haaland, Benjamin
Henry, N. Lynn
BREAST CANCER RESEARCH AND TREATMENT, 2021, 187 (01) : 287 - 294

← 1 2 3 4 5 →